ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EDEN Eden Research Plc

4.25
-0.10 (-2.30%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -2.30% 4.25 4.00 4.50 4.35 4.25 4.35 280,756 09:58:33
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -11.90 26.67M
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.35p. Over the last year, Eden Research shares have traded in a share price range of 3.20p to 12.00p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £26.67 million. Eden Research has a price to earnings ratio (PE ratio) of -11.90.

Eden Research Share Discussion Threads

Showing 5701 to 5723 of 17950 messages
Chat Pages: Latest  238  237  236  235  234  233  232  231  230  229  228  227  Older
DateSubjectAuthorDiscuss
02/1/2019
10:29
Article in the Times newspaper today.

hxxps://www.thetimes.co.uk/article/big-rise-in-companies-forced-off-aim-market-c9djlf69f

Standard fair about AIM companies delisting. Also,

"Aim, originally the Alternative Investment Market, was launched by the London Stock Exchange in 1995. With less onerous listing requirements than the main market, it was designed for smaller, growing companies seeking access to funds to expand. Critics have long argued that its regulation is too weak"

Communication should be regulated too. Far too many companies come to market via an IPO and then start accessing placing monies, but give little back in return. It's a two way street. Money requested and received should place the onus on the Company concerned to deliver proper structured newsflow, outside of RNS channel that is not an RNS requirement.

Education is the key to understanding or as Benjamin Franklin said "An investment in knowledge pays the best interest".

No one invested in Eden has been paid any interest!

investingisatrickygame
02/1/2019
09:46
Chrischas,

Why September 2019 when Lykele said early last year we are at an inflexion point and "in short order", plus I think we are due news on Sipcam/Sustaine now, TT now, Bayer now, all as defined by Eden.

I think Eden has to take a more responsible approach to the share price. Everyone has had dead money here for the last two years when so much has been achieved. Meanwhile, management take decent salaries, bonuses and options, maybe in line with other AIM execs, but that is not really the measure is it!

They owe the share price based on their packaged income which to my mind is currently out of sync with share price performance.

Even Mourinho had a great product (team), but performance was out of sync and he got the boot. Maybe a silly analogy for some, but it does explain the point. Like Mourinho, is management getting the best out of our share price?

I'd argue no!!!!!!!

investingisatrickygame
02/1/2019
09:22
Brucie5,

I'm always wrong, but I think we should be 50pence now based on current and imminent income streams!

Chrischas

I too understand we have world leading products and if so, why are we valued at a paltry £25 million!

Your management point is a reasonable observation and we have yet to understand the value of Lykele. I think current management is way too shy about telling their story. Institutions are still not buying so tell them the story another day. Tell those who will listen and invest.

Personally, with Eden's apparent world class tech, I hope they get taken out and soon. That won't appeal to many, but when you contribute nothing to share price management and fair value, it's best that someone else takes control.

Eden's interest in its private investors, the majority of its share register and those currently capable of moving the share price, is woeful.

investingisatrickygame
02/1/2019
09:19
The Masters of the Redwings are making The Imagineer look like a Prophet.

"For the gate is small, and the way is narrow that leads to Head Lice Lotion , and few are those who find it".

Mathew 7:13-23 .

supersonico
02/1/2019
08:57
Investing

For a company that has world leading products the company and board is and has been remarkably quiet. The new competition will be catching up in the new regulatory environment. Maybe even sidestepping it with completely new Bio products.
I am frustrated that board(top management) is too small to handle what they have.

However I do believe that there will be growth in the share price.I have always targeted Sept 2019 as the most likely take off point now.Eden has to start putting itself about more to achieve this . As I have intimated the competition is not standing still and that is my biggest fear

chrischas
02/1/2019
08:13
Investing, come on then, get off the fence: what's your end of year price?
brucie5
01/1/2019
23:50
Brucie5 said

"We gonna have a share competition this year? Investing, this is your opportunity to get it right second time... ;)

Brucie price: a modest 35p."

I'd be happy to get it right second time. Equally, if the Company was more expansive then I think we would have a better chance of hitting some of our own price targets, don't you?!

Chrischas said

"The price will go up. Though not to the initial potential that it should have done. It needs more dynamicity to get it to its true potential. Sadly, this is a very British company that does not shoot for the stars."

What do you mean, "not to the initial potential that is should have done". Can you explain please.


What is the dynamic you think it needs and why? I'd be very interested in your thought's on this matter.

Finally, why do you think Eden is not shooting for the stars and what is it that you think they are doing?

investingisatrickygame
01/1/2019
19:42
Back after my holiday. The price will go up.Though not to the initial potential that it should have done.It needs more dynamicity to get it to its true potential.Sadly this is a very British company that does not shoot for the stars.
However ,it will have a greater value . The vigorous companies with expansion and personnel to take the company on are not there.
Had a great holiday,my son got engaged and and a lot more commuting across the pond is on the cards.Maybe Eden will offer me a job ?

chrischas
01/1/2019
19:18
SuperIt would be pleasing to learn that TT's products are launched and income is being generated by TT though, I presume, it will be quite small for a few months or even a year. Unlikely to see a queue outside Lidl or Aldi in Monday. I haven't seen any promotions or advertising by parties concerned.Last time I read, UK Head lice business was close to £17m. What % does TT aim to capture ?
northwick
01/1/2019
19:17
This for 2019 FY, Northwick; chin up, best foot forward.

Seriously, I have to question the logic of selling now, if you're serious...

brucie5
01/1/2019
19:08
One would be lucky to see 20p by end of March let alone 35pI have been let down by Eden and I cannot see myself holding onto my investments beyond end of next week. Need to move on.
northwick
01/1/2019
16:56
We gonna have a share competition this year? Investing, this is your opportunity to get it right second time... ;)


Brucie price: a modest 35p.

brucie5
01/1/2019
14:51
Countdown..Kids Back to school Mon 7th January 2019 anyone found TT Head Lice Lotion?
supersonico
31/12/2018
21:32
Yup. Happy New Year to you all. Thanks for your various inputs, and may 2019 see at least some of this potential come good!
brucie5
31/12/2018
19:04
Wishing everyone All the Very Best In The Coming Short Order 2019.
supersonico
31/12/2018
17:00
Agrauxine; ( subsidiary of Biotech group, Lesaffre ), interesting company who participated in the Biocontrol LATAM Conference as Emanuele Medico of Eastman did where he presented Cedroz. Part of the growing Biocontrol / Biopharma industry.
supersonico
31/12/2018
13:50
If you want straight answers ask Mj..she has Bread .

I just have Breadcrumbs and like watching Redwings on a Holly bush.

The question I never need to ask myself is,

Why do the Redwings Come?

5301

supersonico
31/12/2018
13:38
Here is another clue Spadey; @5m.9s
supersonico
31/12/2018
13:20
Oh don't go Mj I'll miss all the unconstructive labelling of me and my posts.

Stay if only to rescue the Gullible and Misled.

supersonico
31/12/2018
13:13
Some of the nonsense you come out with is laughable and you are misleading people; for whatever reason I have no idea but I am sure that most people realise that. I will leave you to it! You have a vivid imagination that is for sure.

Happy New Year

mirandaj
31/12/2018
12:56
And now of all times after spending much time in other places as you say, why does she choose to visit this thread to specifically target Supersonico and while she's at it fails to answer the most pertinent Gin Joint question of the day.
supersonico
31/12/2018
12:43
Mj arrives on the scene purely to comment on Supersonico posts.

I think if you check you'll find Miranda has been "on the (Eden) scene" for a very long time. She just doesn't post frequently on this thread.

redhill9
31/12/2018
12:19
The answer is at 1m.58s
supersonico
Chat Pages: Latest  238  237  236  235  234  233  232  231  230  229  228  227  Older

Your Recent History

Delayed Upgrade Clock